SNGX - Soligenix, Inc. Stock Price and Quote

SNGX [NASD]

Index	-	P/E	-	EPS (ttm)	-5.15	Insider Own	0.37%	Shs Outstand	2.87M	Perf Week	-1.96%
Market Cap	5.41M	Forward P/E	-	EPS next Y	-6.60	Insider Trans	0.00%	Shs Float	2.87M	Perf Month	-40.30%
Income	-14.70M	PEG	-	EPS next Q	-1.12	Inst Own	7.30%	Short Float / Ratio	2.41% / 2.38	Perf Quarter	-79.34%
Sales	0.90M	P/S	6.02	EPS this Y	51.40%	Inst Trans	-29.74%	Short Interest	0.07M	Perf Half Y	-72.66%
Book/sh	0.36	P/B	5.22	EPS next Y	-37.50%	ROA	-65.70%	Target Price	61.88	Perf Year	-81.51%
Cash/sh	5.87	P/C	0.32	EPS next 5Y	1.00%	ROE	-261.70%	52W Range	1.75 - 15.00	Perf YTD	-70.50%
Dividend	-	P/FCF	-	EPS past 5Y	19.60%	ROI	-57.50%	52W High	-86.67%	Beta	1.85
Dividend %	-	Quick Ratio	1.80	Sales past 5Y	-39.80%	Gross Margin	24.20%	52W Low	14.29%	ATR	0.34
Employees	13	Current Ratio	1.80	Sales Q/Q	0.00%	Oper. Margin	-	RSI (14)	25.13	Volatility	15.03% 11.78%
Optionable	No	Debt/Eq	9.90	EPS Q/Q	12.90%	Profit Margin	-	Rel Volume	0.45	Prev Close	1.88
Shortable	No	LT Debt/Eq	6.90	Earnings	-	Payout	-	Avg Volume	29.08K	Price	2.00
Recom	2.00	SMA20	-22.63%	SMA50	-56.89%	SMA200	-76.34%	Volume	9,318	Change	6.38%

Jul-28-20

Downgrade

Dawson James

Buy → Neutral

Jan-31-18

Downgrade

H.C. Wainwright

Buy → Neutral

$5.50 → $2.70

Aug-14-17

Reiterated

Maxim Group

Buy

$4 → $5

Jul-17-17

Initiated

H.C. Wainwright

Buy

$11

Mar-09-23 07:30AM	Soligenix Submits Type A Meeting Request to U.S. FDA for HyBryte New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma PR Newswire +6.62%
Feb-16-23 11:54AM	Soligenix, Inc: Vital Vaccine Development Program has Potential to Address Future Marburg Virus Outbreaks NewMediaWire
Feb-14-23 09:55AM	Why Are Soligenix Shares Plummeting Today? Benzinga -18.10%
07:59AM	UPDATE 1-U.S. FDA declines to review Soligenix's cancer drug Reuters
07:30AM	Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma PR Newswire
07:30AM	Loading…
Feb-09-23 07:30AM	Soligenix Announces Reverse Stock Split PR Newswire -13.02%
Jan-19-23 07:30AM	Soligenix Invited to Present at the Virtual Investor Summit Event PR Newswire
Jan-12-23 08:30AM	Soligenix On Track to Deliver Important Front-Line Treatment to US Market in 2024 NewMediaWire
Jan-09-23 05:36AM	SNGX: Seeking Potential Reverse Stock Split Zacks Small Cap Research
Dec-23-22 04:01PM	Soligenix Announces Distribution of Series D Preferred Stock to Holders of its Common Stock PR Newswire
Dec-20-22 08:30AM	Soligenix Delivers Two Pivotal Milestones NewMediaWire
07:30AM	Soligenix Announces Publication Demonstrating Positive Correlates of Protection with RiVax® in Non-Human Primate Survival after Ricin Challenge PR Newswire
Dec-19-22 07:30AM	Soligenix Initiates Phase 2 Clinical Trial of SGX302 (synthetic hypericin) for the Treatment of Mild-to-Moderate Psoriasis PR Newswire
Dec-16-22 12:09PM	7 Stocks to Add to Your 10x Watchlist InvestorPlace
05:52AM	SNGX: HyBryte NDA Submitted Zacks Small Cap Research
07:30AM	Loading…
Dec-15-22 07:30AM	Soligenix Announces Submission of New Drug Application to the FDA for HyBryte in the Treatment of Cutaneous T-cell Lymphoma PR Newswire +13.48%
Dec-06-22 08:30AM	Soligenix Positioned for Growth: Late-stage Pipeline and Key Q4 Milestones NewMediaWire -5.43%
Nov-16-22 10:28AM	UPDATE: Soligenix, Inc. to Showcase 2022 Milestones in Business Update Fireside Chat with PCG Advisory NewMediaWire
07:00AM	Soligenix, Inc. to Showcase 2022 Milestones in Business Update Fireside Chat With PCG Advisory NewMediaWire
Nov-15-22 07:30AM	Soligenix to Receive $1.2 M in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program PR Newswire -6.80%
Nov-14-22 05:39AM	SNGX: HyBryte NDA to be Submitted Before the End of 2022 Zacks Small Cap Research
Nov-13-22 07:12AM	Soligenix Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag Simply Wall St.
Nov-11-22 09:30AM	Investor Summit Group Announces Soligenix, Inc. To Present at Q4 Conference Newsfile
Nov-10-22 07:30AM	Soligenix Announces Recent Accomplishments And Third Quarter 2022 Financial Results PR Newswire
Nov-07-22 09:30AM	New to The Street Announces Five Corporate Interviews on Episode #404, Airing on the Fox Business Network, Tonight, Monday, November 7, 2022, at 10:30 PM PT GlobeNewswire
Oct-28-22 06:45AM	SNGX: Invited to Submit BARDA Contract Proposal for Filovirus Vaccines Zacks Small Cap Research
Oct-27-22 07:30AM	Soligenix Invited to Submit BARDA Contract Proposal for Development of Thermostabilized Subunit Vaccines for Sudan Ebola and Marburg Viruses PR Newswire
Oct-25-22 07:30AM	Soligenix Announces Formation of Psoriasis Medical Advisory Board PR Newswire
Oct-24-22 09:30AM	New to The Street TV Announces its 399th Show, Featuring Five Corporate Interviews, Airing on the Fox Business Network, Tonight, Monday, October 24, 2022, at 10:30 PM PT GlobeNewswire +8.09%
Oct-21-22 09:30AM	New to The Street / Newsmax TV Announces its Nine Corporate Interviews for This Week's TV Broadcast, Episode #398, October 23, 2022, 10-11 AM ET GlobeNewswire
08:30AM	Loading…
Oct-20-22 08:30AM	Soligenix Announces Adjournment of Annual Meeting and Information for Reconvened Meeting PR Newswire
Oct-17-22 10:16AM	UPDATE: New to The Street to Feature Soligenix Appearances on Its Syndicated Televised Outlets GlobeNewswire +5.44%
08:30AM	New to The Street to Feature Soligenix Appearances on Its Syndicated Televised Outlets GlobeNewswire
Oct-13-22 08:30AM	Soligenix Enters Q4 With Multiple Catalysts in Play Newsfile
Sep-23-22 07:30AM	Soligenix Announces Partial Adjournment of Annual Meeting and Information for Reconvened Annual Meeting PR Newswire -5.85%
Sep-12-22 08:30AM	FDA Awards $2.6 Million Grant for Expanded Study of Soligenix's Hybryte(TM) for CTCL Newsfile
Sep-08-22 07:30AM	Soligenix to Present at the H.C. Wainwright 24th Annual Global Investment Conference PR Newswire
Sep-06-22 07:30AM	U.S. Food and Drug Administration Awards $2.6 Million Orphan Products Development Grant for Expanded Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma PR Newswire
Aug-22-22 09:54AM	Is Soligenix (NASDAQ:SNGX) Using Too Much Debt? Simply Wall St.
Aug-18-22 09:40AM	SNGX: Receives IND Clearance for Phase 2 Clinical Trial in Psoriasis Zacks Small Cap Research -7.14%
Aug-16-22 07:00AM	Presenting on the Emerging Growth Conference on August 17 Register Now GlobeNewswire
Aug-12-22 07:30AM	Soligenix Announces Recent Accomplishments And Second Quarter 2022 Financial Results PR Newswire
Jul-27-22 07:30AM	Soligenix Receives Agreement from FDA on Initial Pediatric Study Plan for HyBryte for the Treatment of Cutaneous T-Cell Lymphoma PR Newswire
Jul-26-22 09:27AM	Soligenix's HyBryte(TM) Treatment Now Within Reach for Rare Cancer Patients Newsfile +6.38%
Jul-25-22 09:16AM	Soligenix Partners With SERB Pharmaceuticals To Supply Ricin Antigen For Ricin Toxin Poisoning Treatment Benzinga +8.78%
07:30AM	Soligenix Announces Strategic Partnership with SERB Pharmaceuticals to Supply its Novel Ricin Antigen PR Newswire
Jul-20-22 03:16PM	Soligenix Shares Gain On HyBrytes Data From Blood Cancer Study Benzinga +11.06%
11:17AM	HyBryte Phase 3 FLASH Study for the Treatment of Cutaneous T-Cell Lymphoma Published in JAMA Dermatology PR Newswire
Jun-28-22 07:30AM	Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in the Treatment of Psoriasis PR Newswire
Jun-27-22 06:30AM	SNGX: Bivalent Filovirus Vaccine Candidate Provides 100% Protection in Non-Human Primates Zacks Small Cap Research
Jun-23-22 07:30AM	Soligenix Announces Successful Protection using a Bivalent Thermostabilized Filovirus Vaccine PR Newswire
Jun-07-22 08:30AM	Soligenix Moves Forward with Treatments for Cutaneous T-Cell Lymphoma and Psoriasis Newsfile
Jun-03-22 08:00AM	Celularity Appoints Industry Leader Diane Parks to its Board of Directors GlobeNewswire -5.45%
Jun-01-22 07:30AM	Key Binding Characteristics of Dusquetide to Important Intracellular Protein Identified PR Newswire -6.29%
May-23-22 07:30AM	Soligenix Receives US Patent Allowance for its Thermostabilized Vaccine Platform PR Newswire +10.36%
May-19-22 10:30AM	SNGX: Phase 2a Trial of SGX302 in Psoriasis to Initiate in Second Half of 2022 Zacks Small Cap Research +10.74%
May-18-22 07:30AM	Soligenix to Present at the H.C. Wainwright Global Investment Conference PR Newswire
May-13-22 07:30AM	Soligenix Announces Recent Accomplishments And First Quarter 2022 Financial Results PR Newswire -6.68%
Apr-19-22 07:30AM	Soligenix Receives $1.4M in Non-Dilutive Government Funding PR Newswire
Mar-31-22 10:36AM	SNGX: NDA Filing for HyBryte in 2022 Zacks Small Cap Research
Mar-29-22 07:30AM	Soligenix Announces Recent Accomplishments And Year-End 2021 Financial Results PR Newswire
Mar-17-22 09:35AM	Soligenix's COVID-19 Vaccine Candidate As Booster Neutralizes Delta, Omicron Variants Benzinga
07:30AM	Soligenix COVID-19 Vaccine, CiVax, Boosts Neutralizing Activity against SARS-CoV-2, including Delta and Omicron PR Newswire
Mar-15-22 02:12PM	Is Soligenix (NASDAQ:SNGX) Using Too Much Debt? Simply Wall St.
Mar-02-22 08:45AM	SG Blocks, Inc. Leads Round of Investment for Moliving, Inc. Business Wire
07:30AM	Soligenix to Present at the Q1 Virtual Investor Summit PR Newswire
Mar-01-22 03:04PM	Soligenix, Inc. to Present at the Q1 Virtual Investor Summit Newsfile -5.32%
Feb-08-22 07:30AM	Soligenix to Present at the 2022 BIO CEO & Investor Conference PR Newswire
Jan-13-22 10:18AM	SNGX: Multiple Milestones Ahead in 2022 Zacks Small Cap Research
Jan-12-22 12:00PM	Soligenix Corporate Update Includes NDA Plans for HyBryte(TM) Newsfile
Jan-10-22 07:30AM	Soligenix Corporate Update Letter - Key Highlights and Upcoming Catalysts PR Newswire
Jan-06-22 07:30AM	Soligenix to Present at Upcoming Investor Conferences PR Newswire
Jan-04-22 07:30AM	Dusquetide Demonstrates Positive Anti-tumor Efficacy in Multiple Nonclinical Animal Studies PR Newswire +5.94%
Dec-02-21 07:30AM	Soligenix Announces Successful Protection using a Bivalent Thermostabilized Filovirus Vaccine PR Newswire
Nov-30-21 08:30AM	Soligenix Proof of Concept Uncovers Potential Treatment Option for the World's 125 Million Psoriasis Sufferers Newsfile
Nov-22-21 04:23AM	SNGX: Durable Immunity for RiVax® Vaccine Zacks Small Cap Research
Nov-12-21 07:30AM	Soligenix Announces Recent Accomplishments And Third Quarter 2021 Financial Results PR Newswire
Nov-08-21 07:30AM	Soligenix Granted Pediatric Investigational Plan Waiver for HyBryte in CTCL in the United Kingdom PR Newswire
Nov-04-21 07:30AM	Soligenix Announces Publication Demonstrating Enduring Protection of its Thermostable RiVax® Vaccine PR Newswire
Nov-01-21 07:30AM	Thermostable Vaccine Technology Platform to be Presented at the 6th International Conference on Vaccines Research and Development PR Newswire
Oct-13-21 08:30AM	Highlights and Insights into Soligenix Newsfile
Oct-12-21 07:30AM	HyBryte FLASH Study Selected as a 'Top Poster' Winner for Presentation at the National Organization for Rare Disorders' Rare Diseases and Orphan Products Breakthrough Summit PR Newswire
Oct-07-21 08:30AM	Vaccine from Soligenix Could Accelerate Global Recovery from COVID-19 Pandemic Newsfile
Sep-29-21 08:21AM	SNGX: CiVax Shows Protective Effects Against SARS-CoV-2 Variant in Non-Human Primates Zacks Small Cap Research
Sep-28-21 07:30AM	Soligenix Announces Accelerated Publication Demonstrating Efficacy and Broad Neutralizing Activity of its COVID-19 Vaccine in Non-Human Primates PR Newswire +5.77%
Sep-27-21 07:30AM	Soligenix Invited to Present at the Cantor Fitzgerald Global Healthcare Conference PR Newswire
Sep-16-21 01:14PM	Soligenix To Test Synthetic Hypericin In Psoriasis Patients Benzinga
07:30AM	Soligenix to Advance Synthetic Hypericin Development in Psoriasis PR Newswire
Sep-14-21 08:30AM	Soligenix Develops Groundbreaking Vaccine Platform to Target Future Pandemics Newsfile +5.56%
Sep-13-21 12:31PM	Is Soligenix (NASDAQ:SNGX) Using Too Much Debt? Simply Wall St. -6.90%
Sep-09-21 07:30AM	FDA Grants Soligenix Orphan Drug Designation for the Treatment of T-cell Lymphoma PR Newswire +10.48%
Aug-24-21 08:30AM	Soligenix: Developing Tools to Tackle the Next Potential Pandemic; PCG Digital Biotech Watch Review PR Newswire
Aug-23-21 07:30AM	Soligenix Announces Publication Demonstrating Successful Formulation and Heat Stabilization of Filovirus Vaccine Platform for Ebola and Marburg Virus Diseases PR Newswire
Aug-19-21 05:30AM	SNGX: Positive Preclinical Data for Filovirus Vaccine Candidates Zacks Small Cap Research -6.36%
Aug-18-21 11:41AM	Soligenix Unveils Preclinical Data From Filovirus Vaccine Candidates Benzinga +6.91%
08:52AM	Soligenix Announces Positive Preclinical Data with Multiple Heat Stable Filovirus Vaccine Candidates PR Newswire
Aug-13-21 07:30AM	Soligenix Announces Recent Accomplishments And Second Quarter 2021 Financial Results PR Newswire
Jul-29-21 08:30AM	Who Is Preparing Us for the Next Potential Pandemic? Newsfile
Jul-22-21 08:30AM	HyBryte(TM): Addressing an Unmet Need for Rare Lymphoma Newsfile
Jul-08-21 11:20AM	50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021 ACCESSWIRE

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SCHABER CHRISTOPHER J	CHAIRMAN, CEO AND PRESIDENT	May 18	Buy	0.44	20,000	8,866	90,095	May 18 06:01 PM
Straube Richard	SENIOR VICE PRESIDENT AND CMO	May 18	Buy	0.50	8,000	4,000	8,000	May 18 06:02 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience